Tom Hallam, Palisade Bio CEO
Palisade Bio is the latest to restructure, hunkering down on its lead program
Like so many other biotechs in the bear market, Palisade Bio is looking to play the reorg game and lay off parts of its staff …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
